Tacrolimus immediate-release formulations are authorised for use in preventing organ rejection in adult and paediatric patients undergoing allogeneic liver, kidney, heart, or lung transplants when used in combination with other immunosuppressant. When paired with other immunosuppressant, tacrolimus extended-release formulations are approved for the prevention of organ rejection in adult and...
The global tacrolimus market is witnessing increasing demand owing to rising number of organ transplant procedures globally. Tacrolimus is an immunosuppressant drug which is widely used to prevent the body from rejecting a transplanted organ like kidney, liver, or heart. The demand for tacrolimus is increasing as it is considered as one of the core drugs in preventing organ rejection...
The future of Tacrolimus looks promising, with ongoing advancements and potential applications in various medical fields. Researchers are exploring novel drug delivery systems to enhance the efficacy and reduce side effects of Tacrolimus, such as nanoparticle formulations and targeted delivery mechanisms. Additionally, studies are underway to investigate the role of Tacrolimus in other...
Tacrolimus is a very important immunosuppressant drug used in organ transplantation to prevent rejection. In this article, we will discuss what tacrolimus is, how it works, its use in transplant patients and some important safety considerations.
Tacrolimus, also known as FK506, is a macrolide immunosuppressant produced by Streptomyces tsukubaensis. It was first discovered in 1984 from soil...